Baird analyst Timothy Wojs maintains AZEK Co (NYSE:AZEK) with a Outperform and raises the price target from $27 to $30.
A Closer Look at 7 Analyst Recommendations For NovoCure
7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of…